Skip to content

Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)

Stratification of Chronic Alcoholic Liver Diseases (SCALE Study) Based on Organs Injury: a Multi-center Prospective Observational Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03295812
Acronym
SCALE
Enrollment
3000
Registered
2017-09-28
Start date
2017-11-16
Completion date
2020-12-30
Last updated
2018-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholic Liver Disease

Brief summary

Recent years, the European Association for the Study of the Liver-chronic liver failure (EASL-CLIF) has defined and graded acute-on-chronic liver failure (ACLF) based on CANONIC study which enrolled cirrhotic patients with acute decompensation. However, the characteristics and definitions of ACLF in non-cirrhotic patients with acute deterioration of liver function and organs injury or failure remain to be clear. As for patients who don't fulfil ACLF criteria, there might be a subgroup with high risk of progression (\>25%) and a moderate 4-week mortality rate (\>7%), which can be defined as pre-ACLF, while the others are just chronic liver disease with mere liver injury or decompensation. This stratification system was primarily verified in a previous retrospective cohort which enrolled Hepatitis B patients only. The stratification criteria for chronic alcoholic liver disease needs to be further defined in detail. Therefore, investigators plan to prospectively recruit 3000 chronic alcoholic hospitalized patients with liver dysfunction from 24 hepatology departments in China, aiming to propose a stratified diagnostic system for chronic alcoholic patients based on organs injury. Meanwhile, risk factors of disease progression and short-term mortality will be analyzed, while characteristics and prognosis will be compared between patients with and without cirrhosis.

Interventions

OTHERstandard therapy

standard therapy,non-interventional study

Sponsors

Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Long-term alcohol consumption (at least one of the followings): 1. \>40g/d for male and \>20g/d for female, at least for 5 years; 2. \>50g/d for at least 6 months; 2. Liver injury (at least one of the followings): 1. AST\>1.0 ULN and AST\>ALT; 2. TBIL\>2.0mg/dl; 3. Ascites; 4. Hepatic encephalopathy; 5. Esophageal variceal bleeding; 6. Hypersplenism

Exclusion criteria

1. Younger than 18 or older than 80; 2. Other etiologies rather than alcoholic liver disease, including but not limited to the followings: 1. Acute or chronic virologic hepatitis: Hepatitis A-E, Hepatitis caused by CMV,EBV, etc. 2. Autoimmune hepatitis, including PSC, PBC, AIH, IgG4 related liver disease 3. Inherited metabolic liver diseases: Wilson disease; 4. Others: Schistosomiasis 3. HIV antibody positive; 4. Malignancies including but not limited to HCC; 5. Pregnancy; 6. Hospital stay less than 24h; 7. Refuse to sigh the informed consent; 8. Combined with other improper situations determined by investigators.

Design outcomes

Primary

MeasureTime frameDescription
4-week mortality4 weeksmortality rate
12-week mortality12 weeksmortality rate

Secondary

MeasureTime frameDescription
4-week progression rate4 weeksThe proportion of subjects progressed to acute-on-chronic liver failure within 4 weeks
24-week mortality24 weeksmortality rate
48-week mortality48 weeksmortality rate

Other

MeasureTime frameDescription
Risk factors for disease progression within 4 weeks4 weeksanalysis of risk factors for disease progression

Countries

China

Contacts

Primary ContactJinjun Chen
chjj@smu.edu.cn0086-18588531001
Backup ContactTingting Qi
tingtingqi@126.com+8615521287260

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026